• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sanofi’s Toujeo beats Lantus at stabilizing blood sugar in T2D patients

September 13, 2017 By Sarah Faulkner

SanofiAdults with Type II diabetes treated with Sanofi‘s (NYSE:SNY) Toujeo Gla-300 insulin glargine had better blood glucose stability than those treated with the company’s Lantus Gla-100 insulin glargine product, according to a study presented at the annual meeting of the European Association for the Study of Diabetes.

The analysis re-analyzed patient data from the Edition II and Edition III clinical trials, which included adults with Type II diabetes, as well as the Senior study, which enrolled elderly patients with Type II diabetes.

Study participants collected self-measured blood glucose data multiple times each day. The data were used to calculate glucose variability and were evaluated alongside hypoglycemia events reported during the studies.

The analysis showed statistically significant reductions in glucose variability and hypoglycemia risk with Toujeo compared to Lantus. The risk differences were most distinct overnight, the company reported.

“The analysis used an innovative risk-based measure, the Low Blood Glucose Index (LBGI), which was calculated using blood glucose level data collected during the studies. This metric was confirmed as a powerful predictor of documented symptomatic (< 3 mmol/L [54 mg/dL]) and severe hypoglycemia among the glycemic variability measures tested. Its clinical relevance lies in the fact that from simple self-measured blood glucose values, it can identify patients who are at high risk of hypoglycemia,” Boris Kovatchev, director of the University of Virginia Center for Diabetes Technology & professor at the University of Virginia School of Medicine, said in prepared remarks.

“Patients treated with Gla-300 achieved lower blood glucose variability and risk of documented symptomatic and severe hypoglycemia, confirmed by LBGI values, consistently in all three clinical trials. The hypoglycemia risk difference in favor of Toujeo was most evident during the night.”

“These data add to the consistent body of evidence around Gla-300, which includes a continuous glucose monitoring study and comparative observational studies like the Deliver program, in patients with Type II diabetes,” Riccardo Perfetti, Sanofi’s VP of global DCV medical affairs, added.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Sanofi-Aventis

IN CASE YOU MISSED IT

  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS